Fidaxomicin versus Vancomycin as a First ‐Line Treatment for Clostridium difficile‐Associated Diarrhea (CDAD) in Specific Patient Populations: A Pharmacoeconomic Evaluation

ConclusionsFidaxomicin as first‐line CDAD therapy is associated with similar total costs as compounded vancomycin oral solution in the general population. In elderly and renally‐impaired patients, slight increases in hospital cost were observed with fidaxomicin therapy, while in patients with cancer or concomitant antibiotic use hospital cost savings were observed.This article is protected by copyright. All rights reserved.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - October 17, 2017 Category: Drugs & Pharmacology Authors: Kelly R. Reveles, Jennifer L. Backo, Frank A. Corvino, Marko Zivkovic, Kelly C. Broderick Tags: Original Research Article Source Type: research